Published Findings

University of California, Los Angeles Neuro-Oncology : A Comprehensive Brain Tumor Program
Contact Us | Directions | Referring a Patient

A leading comprehensive brain tumor program, using molecular diagnostic, gene expression analysis,
cutting edge clinical trials and advanced medical informatics to customize treatment plans for cancer patients.
 Latest Headlines
Roosevelt May Have Had Brain Tumor When He Met Stalin: Books (Bloomberg)
Thu, 28 Jan 2010 05:32:46 GMT
Man with inoperable brain tumor gets 24-year prison term (Terre Haute Tribune Star)
Thu, 28 Jan 2010 04:11:54 GMT
Brain tumor could not slow his drive for life (The Record and Herald News)
Mon, 25 Jan 2010 16:19:15 GMT
Rapid City fifth-grader battles brain tumor (Rapid City Journal)
Wed, 27 Jan 2010 02:13:57 GMT
Beamer basketball coach in fight of her life (Seattle Times)
Thu, 28 Jan 2010 06:11:52 GMT
Alexander Ksendzovsky Named Outstanding 2009 Medical Student By American Brain Tumor Association (Medical News Today)
Fri, 22 Jan 2010 11:29:03 GMT
For Florida boy with brain tumor, a wintry wish comes true (Pioneer Press)
Fri, 22 Jan 2010 06:12:01 GMT
Teva Receives Favorable Court Decision Regarding Generic Temodar(R) (Medical News Today)
Thu, 28 Jan 2010 03:31:09 GMT
Markets in Brief (Haaretz Daily)
Wed, 27 Jan 2010 23:42:30 GMT
Benefit dinner supports Walker Police Department volunteer with brain tumor (The Grand Rapids Press)
Mon, 25 Jan 2010 13:20:36 GMT

* Headlines are from industry sponsored news wires, medical journals and established news organizations from around the world . Please consider the source of the content when viewing the story.
  
 
UCLA begins new Avastin Trials for Patients with grade IV GBM Tumor

UCLA Neuro-Oncology is sponsoring a Phase II trial which will further evalu­ate the safety and effectiveness of Avastin when taken alone or when taken in combination with Irinotecan a topoisomerase inhibitor. Irinotecan is also an FDA-approved drug for the treatment of certain other cancers that directly attacks and damages cancer cells. The study will also determine whether Avastin with or with­out Irinotecan can prevent or slow the growth of the tumor and lead to increase length of survival.


Improving clinical outcomes in glioblastoma brain tumors with genetic analysis

In this study, featured in the New England Journal of Medicine, glioblastomas patients who were treated with gefitinib or erlotinib, were found to be responsive to EGFR kinase inhibitors and strongly associated with coexpression by the tumor of EGFRvIII and PTEN.




UCLA Neuro-Oncology & SiliconMED Launch Online Tool Correlating Gene Expression Levels with Overall Survival of Brain Cancer Patients

Genomic analysis is a powerful new tool permitting unprecedented insights into how brain tumors form and has been enabled primarily through microarray technology. ProbeSetAnalyzer.com, a new web based tool, is aiming to help clinicians and researchers take the massive amount of data created by microarrays and better visualize gene expression levels and how they relate to the overall survival of brain cancer patients.

Most Popular
Clinical Trials
Probe Set Analyzer
Our Team
Brain Tumor Translational Resource
Art of the Brain
Personalized Medicine using Targeted Molecular Therapy
Online Giving
How our Glioblastoma Multiforme Patients Perform

Spring / Summer 2009
Breakthroughs
BM-3-2009


Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model.
Cancer Res
PMID: 19934335 ; 69(23):9133-40

Bevacizumab for recurrent ependymoma.
Neurology
73(20):1677-80.PMID: 19917990

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
J Clin Oncol.
(28):4733-40; PMID: 19720927

Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.
Cancer Res
PMID: 19690143 ; 69(17):6889-98

Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone.
J Neurooncology
PMID: 19655089


All Information content hearof is designed for educational purposes only and is not for the purpose of rendering medical advice or professional services. The information provided should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. Any specific questions you may have regarding an individual's medical condition should be directed to the individual's primary care physician or other attending physician. In addition, if you have or suspect you may have a health problem, you should consult your health care provider.

Portions Copyright (Search, Chart, Content Publishing Tools, Photography, ProviderIQ) 1998-2010 SiliconMED North America

ProviderIQ is a registered trademark of SiliconMED North America and used by permission.

Copyright © 2010 UCLA Neuro-Oncology Program | Timothly Cloughesy MD; Director
All Rights Reserved.

[Content Published:1/28/2010 4:36:37 AM PST]

All Information content hearof is designed for educational purposes only and is not for the purpose of rendering medical advice or professional services. The information provided should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. Any specific questions you may have regarding an individual's medical condition should be directed to the individual's primary care physician or other attending physician. In addition, if you have or suspect you may have a health problem, you should consult your health care provider. Portions Copyright 1998-2010 SiliconMED North America

Copyright © 2010
UCLA Neuro-Oncology
[Content Published:1/28/2010 6:00:10 AM PST]
All Rights Reserved.